Cargando…

Diagnostic and prognostic value of (18)F-FDG PET/CT imaging in suspected recurrence of male breast cancer

PURPOSE: Male breast cancer (MBC) is a rare malignancy, with recurrence being one of the main adverse predictors for prognosis. The aim of the study was to evaluate the diagnostic and predictive value of fluorine-18-fluorodeoxyglucose ((18)F-FDG) PET/CT in the setting of suspected recurrence of MBC....

Descripción completa

Detalles Bibliográficos
Autores principales: Vadi, Shelvin K., Mittal, Bhagwant R., Sood, Ashwani, Singh, Gurpreet, Bal, Amanjit, Parihar, Ashwin S., Bhattacharya, Anish, Basher, Rajender K., Kapoor, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282661/
https://www.ncbi.nlm.nih.gov/pubmed/30312217
http://dx.doi.org/10.1097/MNM.0000000000000928
Descripción
Sumario:PURPOSE: Male breast cancer (MBC) is a rare malignancy, with recurrence being one of the main adverse predictors for prognosis. The aim of the study was to evaluate the diagnostic and predictive value of fluorine-18-fluorodeoxyglucose ((18)F-FDG) PET/CT in the setting of suspected recurrence of MBC. PATIENTS AND METHODS: Retrospective analysis of PET/CT findings was performed in 23 previously treated, histologically proven patients with MBC (mean age: 59.3±10.9 years; range: 36–79 years) with suspected recurrence. Kaplan–Meier disease-specific survival analysis was made with respect to histological, hormonal profile as well as PET/CT findings. RESULTS: Of the 23 patients, 19 (82.6%) showed recurrence. Recurrence at primary site with/without regional/distant site recurrence was seen in 12 (52.2%) patients. Only metastatic recurrence without primary site was seen in seven (30.4%) patients. Bone was the most common site of distant metastasis (14/23) followed by lungs (9/23), liver (4/23), brain (2/23), and adrenal (1/23). No recurrence (regional/distant) was noted in 4/23 (17.3%) patients; however, three of them had (18)F-FDG-avid soft tissue lesions in esophagus, rectum and tongue, correspondingly, confirmed as second primaries with histopathology. Disease-specific survival analysis yielded nodal (P=0.01) as well as distant metastases (P=0.02) as the main survival predictors on PET/CT. Lung (P=0.001), followed by liver (P=0.009), and skeletal (P=0.01) metastases were the most adverse survival predictive factors. CONCLUSION: (18)F-FDG PET/CT showed good diagnostic and prognostic utility in recurrent MBC. It was better than bone scan in evaluation of skeletal metastases. Most importantly, (18)F-FDG PET/CT helped in early detection of second malignancy and their clinical management in studied patients.